Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC). The project, entitled, “Genetic Identification of Psilocybin Containing Mushroom,” will utilize KPU-AGC’s state-of-the-art genomics technology to unravel the intricate genetic makeup of Optimi’s psilocybin-containing mushrooms, potentially paving the way for unprecedented advancements in the field of Psilocybin genetics.
Related news for (OPTHF)
- Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
- Optimi Health Obtains U.S. FDA Drug Establishment Registration
- Optimi Health Provides Corporate Update
- Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
- Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement